Hemostemix Inc. (HEM.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.94 Million CAD | 49.07% |
| 2022 | -4.39 Million CAD | 31.27% |
| 2021 | -6.44 Million CAD | 10.79% |
| 2020 | -7.47 Million CAD | -59.14% |
| 2019 | -4.76 Million CAD | 29.31% |
| 2018 | 241.63 Thousand CAD | -136.32% |
| 2017 | -2.37 Million CAD | 23.48% |
| 2016 | -2.67 Million CAD | 7.44% |
| 2015 | -3.92 Million CAD | 7.56% |
| 2014 | -4.29 Million CAD | -188.62% |
| 2013 | -1.48 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -364.06 Thousand CAD | -11.87% |
| 2024 Q1 | -325.71 Thousand CAD | 28.71% |
| 2023 Q1 | -1.13 Million CAD | -80.95% |
| 2023 Q4 | -413.58 Thousand CAD | -132.7% |
| 2023 Q3 | -177.73 Thousand CAD | 63.96% |
| 2023 FY | - CAD | 52.92% |
| 2023 Q2 | -493.19 Thousand CAD | 56.4% |
| 2022 Q1 | -1.33 Million CAD | 61.75% |
| 2022 FY | - CAD | 31.27% |
| 2022 Q2 | -1.58 Million CAD | -18.78% |
| 2022 Q3 | -1.03 Million CAD | 34.45% |
| 2022 Q4 | -625.18 Thousand CAD | 39.8% |
| 2021 Q2 | -1.4 Million CAD | -116.82% |
| 2021 Q4 | -3.48 Million CAD | -112.64% |
| 2021 Q1 | -646.96 Thousand CAD | 83.28% |
| 2021 Q3 | -1.63 Million CAD | -16.91% |
| 2021 FY | - CAD | 10.79% |
| 2020 FY | - CAD | -59.14% |
| 2020 Q4 | -3.86 Million CAD | -166.3% |
| 2020 Q3 | -1.45 Million CAD | 29.0% |
| 2020 Q2 | -2.04 Million CAD | -1623.03% |
| 2020 Q1 | -118.76 Thousand CAD | 78.53% |
| 2019 FY | - CAD | 29.31% |
| 2019 Q3 | -1.29 Million CAD | 0.88% |
| 2019 Q2 | -1.3 Million CAD | 13.43% |
| 2019 Q4 | -553.26 Thousand CAD | 57.25% |
| 2019 Q1 | -1.5 Million CAD | 23.93% |
| 2018 FY | - CAD | -136.32% |
| 2018 Q4 | -1.98 Million CAD | -27.72% |
| 2018 Q2 | -1.79 Million CAD | -37.31% |
| 2018 Q1 | -1.3 Million CAD | -310.75% |
| 2018 Q3 | -1.55 Million CAD | 13.64% |
| 2017 Q2 | -465.09 Thousand CAD | 11.9% |
| 2017 Q4 | 621.1 Thousand CAD | 121.66% |
| 2017 Q3 | -2.86 Million CAD | -516.48% |
| 2017 FY | - CAD | 23.48% |
| 2017 Q1 | -527.89 Thousand CAD | 37.74% |
| 2016 FY | - CAD | 7.44% |
| 2016 Q2 | -617.87 Thousand CAD | 5.44% |
| 2016 Q3 | -1.57 Million CAD | -154.6% |
| 2016 Q4 | -847.84 Thousand CAD | 46.1% |
| 2016 Q1 | -653.4 Thousand CAD | 44.25% |
| 2015 Q1 | -867.34 Thousand CAD | 60.29% |
| 2015 FY | - CAD | 7.56% |
| 2015 Q4 | -1.17 Million CAD | -19.71% |
| 2015 Q3 | -978.93 Thousand CAD | -3.09% |
| 2015 Q2 | -949.57 Thousand CAD | -9.48% |
| 2014 FY | - CAD | -188.62% |
| 2014 Q1 | -9519.00 CAD | 40.39% |
| 2014 Q3 | -826.35 Thousand CAD | -2122.33% |
| 2014 Q2 | -37.18 Thousand CAD | -290.63% |
| 2014 Q4 | -2.18 Million CAD | -164.29% |
| 2013 Q3 | -16.76 Thousand CAD | 52.62% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q1 | -51.84 Thousand CAD | 0.0% |
| 2013 Q4 | -15.97 Thousand CAD | 4.76% |
| 2013 Q2 | -35.39 Thousand CAD | 31.73% |
| 2012 Q3 | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -351.749% |
| Covalon Technologies Ltd. | -3.49 Million CAD | 44.273% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 57.769% |
| Kane Biotech Inc. | -3.23 Million CAD | 39.842% |
| MedMira Inc. | -1.57 Million CAD | -23.365% |
| Marvel Biosciences Corp. | -2.25 Million CAD | 13.599% |
| NervGen Pharma Corp. | -17.72 Million CAD | 89.02% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 69.92% |